• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

An Afternoon with Anthony Scaramucci of Skybridge

Diary, Newsletter

I asked Anthony Scaramucci, CEO and founder of Skybridge Capital, why we should attend his upcoming SALT conference point-blank.

“It’s going to be exciting,” he said.

“How exciting?” I enquired.

“I’ve invited former White House chief of staff General John F. Kelley to be my keynote speaker.” General Kelley, an old friend from my Marine Corps days, fired Anthony after only eight days on the job as Donald Trump’s Press Secretary.

“That’s pretty exciting,” I responded. “Humble too.”

This was the answer that convinced me to attend the May 7-10 SkyBridge Alternative asset management conference (SALT) at the Las Vegas Bellagio Hotel. You all know the Bellagio. That is the casino that was robbed in the iconic movie Oceans 11.

That is not all Scaramucci had to offer about the upcoming event, known to his friends since his college days as “The Mooch”.

Among the other headline, speakers are former UN ambassador Nikki Haley, AOL Time Warner founder Steve Case, artificial intelligence guru Dr. Kai-fu Lee who I have written about earlier, and Carlyle Group co-founder David Rubenstein.

SALT will give seasoned investors to update themselves on the hundreds of alternative investment strategies now in play in the market, raise or allocate money, meet fascinating people, and just plain have fun. Some SkyBridge services accept client investments as little as $25,000. Their end of conference party is legendary.

SkyBridge is led by Co-Managing Partners Anthony Scaramucci and Raymond Nolte.  Ray serves as the Firm’s Chief Investment Officer and Chairman of the Portfolio Allocation and Manager Selection Committees.  Anthony focuses on strategic planning and marketing efforts.

While I had “The Mooch” on the phone, I managed to get him to give me his 30,000-foot view of the seminal events affecting markets today.

The proliferation of exchange-traded funds and algorithms will end in tears. There are now more listed ETFs than listed stocks, over 3,500.

The normalizing of interest rates is unsustainable, which have been artificially low for ten years now. One rise too many and it will crash the market. The next quarter-point rise could be the stick that breaks the camel’s back (an appropriate metaphor for a desert investment conference).

However, rising rates are good for hedge funds as they present more trading opportunities and openings for relative outperformance, or “alpha.”

There has been a wholesale retreat of investment capital from the markets, at least $300 billion in recent years. The end result will be much higher volatility when markets fall as we all saw in the Q4 meltdown until this structural weakness has been obscured by ultra-low interest rates. The good news is that banks are now so overcapitalized that they will not be at risk during the next financial crisis.

Ever the contrarian and iconoclast, Scaramucci currently has no positions in technology stocks. He believes the sector has run too far too fast after its meteoric 2 ½ year outperformance and is overdue for a rest. Earnings need to catch up with prices and multiples.

What is Anthony’s favorite must-buy stock today? Berkshire Hathaway (BRK/A), run by Oracle of Omaha Warren Buffet,  is almost a guarantee to outperform the market. Scaramucci has owned the shares in one form or another for over 25 years.

While emerging markets (EEM) are currently the flavor of the day, Anthony won’t touch them either. The accounting standards and lack of rule of law are way too lax for his own high investment standards.

SkyBridge is avoiding the 220 IPOs this year which could total $700 billion. Many of these are overhyped with unproven business models and inexperienced management. The $100 billion in cash they actually take out of the market won’t be enough to crash it.

SkyBridge Capital is a global alternative investment firm with $9.2 billion in assets under management or advisement (as of January 31, 2019). The firm offers hedge fund investing solutions that address a wide range of market participants from individual investors to large institutions.

SkyBridge takes a high-conviction approach to alpha generation expressed through a thematic and opportunistic investment style. The firm manages multi-strategy funds of hedge funds and customized separate account portfolios, and provides hedge fund advisory services. SkyBridge also produces a large annual conference in the U.S. and Asia known as the SkyBridge Alternatives Conference (SALT).
 
Finally, I asked Anthony, if he were king of the world what change would he make to the US today? “If I could wave a magic wand, I would reduce partisanship,” he replied. “It prevents us from being our best.” Will he ever go back into politics again? “Never say never,” he shot back wistfully.

With that, I promised to give him a hug the next time I see him in Vegas which I have been visiting myself since 1955 during the rat pack days.
 
To learn more about SkyBridge, please visit their website here.

To obtain details about the upcoming May 7-10 SALT conference at the Bellagio Hotel in Las Vegas, please click here. Better get a move on. Their discount pricing for the event ends on March 15. Institutional Investors are invited free of charge.

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2018/11/John-Thomas-with-lady-in-red.png 495 541 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 04:02:212020-05-11 14:14:33An Afternoon with Anthony Scaramucci of Skybridge
Mad Hedge Fund Trader

Biogen’s Big Alzheimer’s Bet

Biotech Letter

Biotech giant Biogen (BIIB) failed to impress in 2019. Surprisingly, the company is sticking to its strategy this 2020.

Despite the majority of biotech companies posting market-beating gains last year, Biogen’s shares suffered a 1.4% loss to their value. Taking a look at its performance, there are three obvious reasons why Biogen stock lost ground in 2019.

For one, its revenue generation, particularly for the multiple sclerosis portfolio, flatlined last year. Another reason is the company’s move not to acquire another company the way Bristol-Myers Squibb (BMY) took over Celgene.

Biogen’s decision to not make any major acquisition in 2019 was deemed as an inability to achieve significant business development milestones, thereby failing to positively influence the company’s near-term outlook.  

The third reason is Biogen’s decision to halt trials for its widely anticipated Alzheimer’s drug candidate, Aducanumab, in March 2019.

With so much invested in the development of this product, the investing community expected Biogen to completely drop the project altogether.

However, it seems that Biogen has found a way to resolve the issues it initially encountered in the Aducanumab study.

In October 2019, the company announced its plan to resurrect all its Aducanumab-related efforts. To show its commitment to the plan, Biogen kicked off 2020 with a massive purchase from Pfizer (PFE).

Since Biogen aims to apply for regulatory approval by early 2020, the company has been aggressively pursuing avenues to ensure that its Alzheimer’s drug candidate will get the green light as soon as possible.

One of its efforts is its $700 million deal to buy Pfizer’s castoff drug, PF-05251749.

The Pfizer drug was created to treat Irregular Sleep-Wake Rhythm Disorder suffered by Alzheimer’s and Parkinson’s disease patients. This condition, also known as Sundowning, affects 20% of those afflicted by these neurological diseases.

According to the terms of the deal, Biogen will shell out $75 million upfront to gain the rights to the Pfizer drug.

The company will also pay an additional $635 million in the form of milestone payments. Pfizer will receive tiered royalties as well.

On top of this $700 million deal with Pfizer, Biogen also added another $45 million to fund its Alzheimer’s research with Ionis Pharmaceuticals (IONS). Apart from these, the two companies have been working on ION859, which is a possible treatment for Parkinson’s disease.

As if all of these are not enough to show Biogen’s dedication to finding the cure for Alzheimer’s disease, the company has a similar drug in its pipeline: BAN2401. This new drug, which uses a similar approach to Aducanumab, is actually already in its late-stage testing phase.

However, Biogen’s deal with Pfizer is not the first of its kind.

Prior to this, the company paid a whopping $300 million upfront to Bristol-Myers Squibb to own the rights to neurological drug Gosuranemab. Unfortunately, that study failed to deliver the desired results.

Even though Biogen has yet to actually file for regulatory approval for Aducanumab, the company is already preparing for the treatment’s launch this year. This is a rather confident move especially in light of the niggling doubts on the drug’s approval.

Apart from working on Aducanumab, Biogen has been testing for a higher dosage for spinal muscular atrophy medication Spinranza. This is done as a precautionary measure against Novartis’ (NVS) blockbuster gene therapy Zolgensma.

Its exclusive rights on Tecfidera, which has been challenged by Mylan (MYL), is also anticipated to hold until 2028. This means Biogen can still expect to reign supreme in this niche, hanging on to its blockbuster drug that raked in $4.3 billion in 2018 alone and $2.15 billion in the first half of 2019.

In addition to Alzheimer’s and Parkinson’s disease, Biogen is active in searching for treatments for Lou Gehrig’s disease along with stroke and choroideremia as well.

Biogen has also set in motion its plan to venture into rare eye diseases via its $800 million acquisition of Nighstar Therapeutics back in June 2019.

Notably, though, Biogen has been steering away from any major acquisition in 2020.

This strategy could be a stroke of genius if the company’s bet on Aducanumab pays off.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2020/01/biogen.png 312 899 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 04:00:362020-01-23 10:57:00Biogen’s Big Alzheimer’s Bet
Mad Hedge Fund Trader

January 22, 2020 - MDT Alert (DOCU)

MDT Alert

Today, I would like to make a suggestion on a debit spread. The stock is Docusign, Inc. (DOCU).

DOCU is trading at $74.72 as I write this.

I am going to suggest a trade using the February monthly options. DOCU does not have weeklies, and the February monthlies will allow enough time to see if the stock continues to run.

My suggestion today is this:

Buy to Open February 21st - $75.00 call @ $2.45

Sell to Open February 21st - $80.00 call @ $0.70

Net debit is $1.75 per spread with a maximum gain of $3.25 per spread if DOCU trades above $80.00 by February 21st.

Based on the nominal portfolio, limit the trade to 5 spreads or 0.8% of the portfolio.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-22 15:15:502020-01-22 15:15:50January 22, 2020 - MDT Alert (DOCU)
Mad Hedge Fund Trader

January 22, 2020 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-22 09:24:492020-01-22 09:24:49January 22, 2020 - MDT Pro Tips A.M.
Mad Hedge Fund Trader

January 22, 2020

Diary, Newsletter, Summary

Global Market Comments
January 22, 2020
Fiat Lux

Featured Trade:

(LAST CHANCE TO ATTEND THE TUESDAY, FEBRUARY 4 SYDNEY, AUSTRALIA STRATEGY LUNCHEON)
(WHY THERE’S ANOTHER DOUBLE IN CRISPR THERAPEUTICS)
(CRSP), (BLUE), (EDIT), (NVS), (GILD)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-22 04:06:472020-01-21 17:44:46January 22, 2020
Mad Hedge Fund Trader

SOLD OUT - Tuesday, February 4 Sydney, Australia Global Strategy Luncheon

Diary, Lunch, Newsletter

Come join me for lunch at the Mad Hedge Fund Trader’s Global Strategy Update, which I will be conducting in Sydney Australia at 12:30 PM on Tuesday, February 4, 2020.

An excellent meal will be followed by a wide-ranging discussion and an extended question-and-answer period.

I’ll be giving you my up-to-date view on stocks, bonds, currencies, commodities, precious metals, energy, and real estate.

And to keep you in suspense, I’ll be throwing a few surprises out there too.

Tickets are available for $233.

The lunch will be held at an exclusive downtown hotel the details of which will be emailed with your purchase confirmation.

I look forward to meeting you and thank you for supporting my research. To purchase tickets for this luncheon, please click here.

https://www.madhedgefundtrader.com/wp-content/uploads/2018/10/John-Thomas-Sydney.png 345 377 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-22 04:04:442020-02-05 10:01:52SOLD OUT - Tuesday, February 4 Sydney, Australia Global Strategy Luncheon
Mad Hedge Fund Trader

January 22, 2020

Tech Letter

Mad Hedge Technology Letter
January 22, 2020
Fiat Lux

Featured Trade:

(THE HOLLOW VICTORY FOR TECH IN THE CHINA TRADE DEAL)
(MSFT), (AMZN), (HUAWEI)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-22 04:04:122020-01-21 18:38:58January 22, 2020
Mad Hedge Fund Trader

Why There’s Another Double in CRISPR Therapeutics

Diary, Newsletter

Occasionally, I discover a piece of research from one of my other Mad Hedge publications that is so important that I send it out to everyone immediately.

Today piece from the Mad Hedge Biotech & Health Care Letter is one of the instances. It makes the case and provides the numbers as to why Biotech & Health Care will be one of two dominant sector to follow for the next decade. It also is a key plank in my argument for a return of a new Golden Age and a second “Roaring Twenties.”

Here it is.

Biotech investors, take note: 2019 was a great year for the industry, but the best is yet to come.

In the final three months of 2019, the biotech sector grew by 32% -- notably outpacing the pharmaceutical industry, which only recorded a 9.5% gain.

However, the biotechnology sector is estimated to grow substantially in 2020, and reach over $775 billion in revenue by 2024 as more and more treatments for previously incurable diseases get discovered.

Looking at all the progress in the biotechnology space, this could even be the year we’d finally discover the cure to many life-threatening and debilitating conditions like cancer and Alzheimer’s disease.

With all these technological advancements, two revolutionary tools have been overhauling the entire biotechnology and healthcare industry from the ground up: precision medicine and CRISPR. Actually, the impressive growth of the biotechnology industry has been largely attributed to the excitement generated by the gene-editing sector.

While the majority of companies concentrating on the human genome are still in the research phase, the growth of this industry is undeniable. 

Here’s tangible proof.

Just 20 years ago, reading all the DNA of a single person cost approximately $3 billion. Now, this price is down to only $1,000. In the future, this number will go even lower at $100. There are now gigantic factories in China sequencing DNA for companies like Ancestry.com and 23andMe.

This is just one example of how the biotechnology industry has grown by leaps and bounds. It’s also the reason behind the surge of CRISPR shares.

In effect, the specialists in this niche, including Crispr Therapeutics (CRSP), Bluebird Bio (BLUE), and Editas Medicine (EDIT), are amplifying their efforts in 2020.

Among the specialist companies, CRISPR Therapeutics is considered as one of the frontrunners -- if not the top stock. This is because compared to its rivals, which are still in preclinical phases of development, CRISPR Therapeutics’ already has two drugs going through Phase 1 trials: CTX001 and CTX110.

The promising results of the company’s research resulted in a 113% rise in shares last year, with the bulk of the surge starting in October. In fact, CRISPR Therapeutics’ performance had been so impressive that its market cap reached $3.4 billion.

CTX001 is created to target patients suffering from genetic blood disorders, specifically sickle-cell disease and transfusion-dependent beta-thalassemia.

Meanwhile, CTX110 is a CAR-T treatment. The process involves the extraction of immune cells from the patient. These are then retrained and later re-introduced to the human body.

CRISPR Therapeutics’ CAR-T treatment is anticipated to be offered at a cheaper price compared to the other CAR-T therapies.

Both Novartis (NVS) and Gilead Sciences (GILD) are pursuing the same treatment. However, the cost of the therapy from the latter two is expected to reach as much as $475,000 for every patient annually.

Apart from CTX001 and CTX110, CRISPR Therapeutics has two more immunology candidates, currently dubbed CTX120 and CTX130.

If both phase trials succeed, these will bring massive home runs for CRISPR Therapeutics, especially since the cancer immunology market is expected to reach $127 billion by 2026. Over the next 10 years, this niche is estimated to reach $25 trillion in sales.

Among the gene-editing treatments under development today, CRISPR is projected to grow tenfold in the number of applications and potentially curing 89% of disease-causing genetic variations by 2026.

Taking this pace into consideration, the valuation for this market is expected to grow from $551 million in 2017 to reach roughly $3.1 billion by 2023 and $6 billion by 2025.

Meanwhile, precision medicine as a whole is estimated to show a significant jump from $48.6 billion in 2018 to $84.6 billion by 2024. In 2028, this market is expected to rake in $216 billion.

Hence, further success with CTX001 and CTX110 along with additional treatments in the drug pipeline would all but guarantee that Crispr Therapeutics could beat the market again in 2020.

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2020/01/biotech.png 337 506 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-22 04:02:382020-05-11 14:14:25Why There’s Another Double in CRISPR Therapeutics
Mad Hedge Fund Trader

The Hollow Victory for Tech in the China Trade Deal

Tech Letter

The Davos World Economic Forum is the optimal place to get a snapshot of the state of the American technology sector and apply its underpinnings to an overall trading strategy for 2020.

Stepping back, one clear theme is the lasting effects of the trade war and how that will manifest itself in the broader tech sector.

We got some serious sound bites from CEO of Microsoft Satya Nadella at Davos who is convinced that mutual economic saber-rattling between the US and China will show up in higher costs because of the misallocation of resources.

The most critical point of contention is the development in the semiconductor space as we move into the 5G world and this $470 billion industry which realizes cost savings from scaling by global supply is splintering off as we speak into two separate industries.  

This just translates into higher costs to source components for your Microsoft Surface laptop or your Apple Ear Buds.

The follow-through effect is ultimately bludgeoning global growth rates and tech intermediaries will be forced to pick up the extra tab or face the looming decision to pass costs on to the consumer.

As we move forward, the administration is considering more limits to US semiconductor companies’ access to the Chinese consumer market.

The scaremongering fueled by the rise and threat of Huawei has reached fever pitch.

Remember that even with the aggression of the American administration hoping to cap Huawei’s revenue explosion, Huawei still managed to grow sales 18% last year to $122 billion.

I can tell you that if the U.S. administration came after the Mad Hedge Technology Letter guns blazing, we wouldn’t be sitting here growing 18% annually!

The U.S. administration hasn’t stopped at Huawei and is putting in shifts attempting to convince other nations to avoid using Chinese infrastructure equipment for the 5G revolution.

The “Phase One” of the trade agreement is largely seen as a moot point in the technology community and in some cases can be argued as a net negative to component makers whose access to the local Chinese market has narrowed.

The agreement signed also delivered no meaningful protection to intellectual property for US technology companies working with China which was largely viewed as the main catalyst provoking a geopolitical fight.

The trade war has sped up the bifurcation of internets, better known as “splinternet,” and I believe that sometime in the near future, you will need to download Chinese software and platforms to function inside of China.

Much of these misunderstandings stem from the lack of trust that has accumulated between the two parties.

The American tech sector and Wall Street have indirectly subsidized China’s technological rise to this point and now they must go head-to-head in every future technology such as artificial intelligence, 5G, fintech, augmented reality, and virtual reality.

This appears to be the new normal - a frosty and adversarial tech relationship.

There is now zero good will between each other.

The trust of tech on American shores could almost be ironically argued that it is worse than the trust level with China.

Edelman’s 20th annual trust barometer surveyed more than 34,000 adult respondents in 38 markets around the world.

It found that 61% of participants said the pace of change in technology is too fast and government does not fully understand emerging technologies enough to regulate them efficiently.

Trust in tech from 2019 to 2020 declined the most significantly in France, Canada, Italy, Russia, Singapore, the U.S. and Australia.

Much of the narrative has been about the domination of American tech by a handful of actors that has seen American companies go up against foreign governments.

France and America recently announced a temporary truce after the French President Emmanuel Macron reached out by phone to President Trump hoping to end the threat of tariffs while they work out a broader accord on digital taxation.

The French leader agreed to postpone until the end of 2020 a tax that France levied on big tech companies last year and in turn, the U.S. will delay the counter-tariffs that were in the works set to be levied on the French.

And it’s not just the French.

India has taken heed from the brooding trouble between the encroachment on sovereignty and American tech giants by adopting an aggressive stance towards Amazon.

Amazon CEO Jeff Bezos' lowlight of a recent India work trip came in the form of being snubbed by the Indian government.

India’s commerce minister Piyush Goyal said, “It’s not as if they (Amazon) are doing a great favor to India when they invest a billion dollars.”

He called Amazon a capital guzzler equating its mounting losses up to “predatory pricing or some unfair trade practices.”

India is on the verge of turning protectionist on foreign tech and this flies in the face of the tech atmosphere even just a few years ago.

Governments have come to realize that America’s FANGs are too dominant and entrenched often resulting in a net negative to the local populace.

More often than not, American tech found ways of rerouting local revenue to coffers of a few billionaires while paying zero local tax.

The easy money has been made and now the Tim Cooks and Sundar Pichais of the world will have to fight tooth and nail with not only the U.S. antitrust regulators, but foreign governments.

This is why a handful of tech companies this dominant has been the outsized winners over the past generation as their share prices have gone from the lower left to the upper right but now command minimal consumer trust.

The ultimate Davos message is that big tech continues to grind higher, but alarm bells have started to ring.

There’s only so much friction they can handle before investors pull the rug.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-22 04:02:102020-05-11 13:08:46The Hollow Victory for Tech in the China Trade Deal
Mad Hedge Fund Trader

January 22, 2020 - Quote of the Day

Tech Letter

“We also welcome any regulation that helps the marketplace not be a race to the bottom.” – Said CEO of Microsoft Satya Nadella

https://www.madhedgefundtrader.com/wp-content/uploads/2020/01/satya-nadella.png 510 354 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-22 04:00:062020-01-21 18:39:07January 22, 2020 - Quote of the Day
Page 5 of 13«‹34567›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top